Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$12.30 -2.1%	$11.32	$3.98 ▼ $13.37	$1.91B	1.92	2.18 million shs	1.50 million shs
CMPX Compass Therapeutics	$2.78 +2.2%	$2.82	$1.15 ▼ $4.08	$376.13M	1.49	1.40 million shs	619,664 shs
SPRY ARS Pharmaceuticals	$14.60 +5.9%	$16.83	$10.00 ▼ $18.90	$1.36B	0.9	1.74 million shs	2.16 million shs
TARS Tarsus Pharmaceuticals	$55.41 +3.2%	$43.20	$25.14 ▼ $57.28	$2.27B	0.79	688,618 shs	816,812 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+1.21%	-0.79%	+20.89%	+38.17%	+161.12%
CMPX Compass Therapeutics	-5.23%	-14.20%	-9.33%	+32.04%	+128.57%
SPRY ARS Pharmaceuticals	-1.71%	-17.23%	-23.05%	-3.02%	-3.16%
TARS Tarsus Pharmaceuticals	-1.67%	+4.56%	+24.16%	+24.33%	+102.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.2553 of 5 stars	1.4	1.0	4.2	1.4	1.7	0.6
CMPX Compass Therapeutics	2.7543 of 5 stars	3.6	1.0	0.0	2.1	5.0	0.0
SPRY ARS Pharmaceuticals	2.651 of 5 stars	3.6	0.0	0.0	2.2	4.2	0.6
TARS Tarsus Pharmaceuticals	1.9711 of 5 stars	2.5	1.0	0.0	3.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	0.65% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.89	362.80% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	111.59% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	19.94% Upside

Current Analyst Ratings Breakdown

Latest CMPX, SPRY, TARS, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	10.46	N/A	N/A	$1.18 per share	10.42
CMPX Compass Therapeutics	$850K	453.07	N/A	N/A	$0.67 per share	4.16
SPRY ARS Pharmaceuticals	$89.15M	16.24	$0.01 per share	1,656.77	$1.95 per share	7.51
TARS Tarsus Pharmaceuticals	$295.52M	7.94	N/A	N/A	$7.88 per share	7.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	11/6/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	N/A
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	N/A
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.33	N/A	N/A	N/A	-31.13%	-32.36%	-21.04%	N/A

Latest CMPX, SPRY, TARS, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.33	-$0.48	-$0.15	-$0.48	$95.81 million	$102.66 million
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
CMPX Compass Therapeutics	N/A	7.66	7.66
SPRY ARS Pharmaceuticals	0.37	6.17	5.98
TARS Tarsus Pharmaceuticals	0.22	5.26	5.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
CMPX Compass Therapeutics	68.43%
SPRY ARS Pharmaceuticals	68.16%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
CMPX Compass Therapeutics	29.80%
SPRY ARS Pharmaceuticals	33.50%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.21 million	38.43 million	Optionable

CMPX, SPRY, TARS, and ADPT Headlines

Recent News About These Companies

Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Invesco Ltd.

August 20 at 3:42 AM | marketbeat.com

Lord Abbett & CO. LLC Acquires 51,714 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 16, 2025 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells 6,000 Shares of Stock

August 15, 2025 | marketbeat.com

Lyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point.

August 15, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells $300,000.00 in Stock

August 14, 2025 | insidertrades.com

Informed Momentum Co LLC Decreases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 14, 2025 | marketbeat.com

Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87

August 12, 2025 | msn.com

Blair William & Co. IL Sells 15,814 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 12, 2025 | marketbeat.com

HC Wainwright Brokers Raise Earnings Estimates for TARS

August 12, 2025 | americanbankingnews.com

Q3 EPS Forecast for Tarsus Pharmaceuticals Raised by Analyst

August 11, 2025 | marketbeat.com

Brokers Offer Predictions for TARS Q3 Earnings

August 11, 2025 | marketbeat.com

HC Wainwright Has Optimistic View of TARS FY2027 Earnings

August 10, 2025 | americanbankingnews.com

Analyst Estimates: Here's What Brokers Think Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Second-Quarter Report

August 9, 2025 | finance.yahoo.com

FY2027 Earnings Forecast for TARS Issued By HC Wainwright

August 9, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Average PT from Brokerages

August 9, 2025 | americanbankingnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 13.4% - What's Next?

August 8, 2025 | marketbeat.com

Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result

August 7, 2025 | finance.yahoo.com

Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum

August 7, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 7, 2025 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, SPRY, TARS, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$12.30 -0.26 (-2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$12.30 -0.01 (-0.04%)

As of 07:36 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Compass Therapeutics NASDAQ:CMPX

$2.78 +0.06 (+2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$2.80 +0.03 (+0.90%)

As of 06:40 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

ARS Pharmaceuticals NASDAQ:SPRY

$14.60 +0.81 (+5.87%)

Closing price 04:00 PM Eastern

Extended Trading

$14.50 -0.09 (-0.65%)

As of 06:41 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Tarsus Pharmaceuticals NASDAQ:TARS

$55.41 +1.71 (+3.18%)

Closing price 04:00 PM Eastern

Extended Trading

$56.00 +0.59 (+1.06%)

As of 06:40 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time